Jan. 3 Financial Quick Takes: Black Diamond plots IPO; plus Oxford Nanopore, CF PharmTech, Mygene and Zerun

Black Diamond seeking NASDAQ listing
Tumor-agnostic precision oncology company Black Diamond Therapeutics Inc. filed for an IPO on NASDAQ worth up to $100 million. Shepherded since 2017 by lead investor Versant Ventures, the company is building a pipeline based on its Mutation-Allostery-Pharmacology (MAP) platform;

Read the full 437 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE